Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Employees - 14,
CEO - Mr. Jack W. Callicutt CPA,
Sector - Healthcare,
Country - US,
Market Cap - 33.70M
Altman ZScore(max is 10): -22.97, Piotroski Score(max is 10): 2, Working Capital: $3408000, Total Assets: $28972000, Retained Earnings: $-389542000, EBIT: -40415000, Total Liabilities: $121453000, Revenue: $80000
AryaFin Target Price - $-0.77 - Current Price $1.04 - Analyst Target Price $11.00
Ticker | GALT |
Index | RUT |
Curent Price | 1.04 |
Change | -48.00% |
Market Cap | 33.70M |
Average Volume | 434.43K |
Income | -41.61M |
Sales | 0.00M |
Book Value/Share | -1.52 |
Cash/Share | 0.84 |
Dividend Est | - |
Dividend TTM | - |
Dividend Ex-Date | - |
Employees | 14 |
Moving Avg 20days | -54.05% |
Moving Avg 50days | -58.60% |
Moving Avg 200days | -60.65% |
Shares Outstanding | 62.31M |
Earnings Date | Nov 14 BMO |
Inst. Ownership | 15.67% |
Price/Earnings | - |
Forwad P/E | - |
PE Growth | - |
Price/Sales | - |
Price/Book | - |
Price/Cash | 1.25 |
Price/FCF | - |
Quick Ratio | 1.13 |
Current Ratio | 1.13 |
Debt/Equity | - |
Return on Assets | -176.31% |
Return on Equity | - |
Return on Investment | -2675.95% |
Gross Margin | - |
Ops Margin | - |
Profit Margin | - |
RSI | 20.85 |
BETA(β) | 0.82 |
From 52week Low | -33.12% |
From 52week High | -75.63% |
EPS | -0.73 |
EPS next Year | -1.65 |
EPS next Qtr | -0.16 |
EPS this Year | 1.35% |
EPS next 5 Year | - |
EPS past 5 Year | -14.30% |
Sales past 5 Year | 0.00% |
EPS Y/Y | 4.53% |
Sales Y/Y | - |
EPS Q/Q | 23.30% |
Sales Q/Q | - |
Sales Surprise | - |
EPS Surprise | 10.00% |
ATR(14) | 0.28 |
Perf Week | -50.71% |
Perf Month | -63.06% |
Perf Quarter | -61.76% |
Perf Year | -39.18% |
Perf YTD | -37.35% |
Target Price | 11.00 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer